However, mitoxantrone has been used less since the advent of monoclonal antibodies to treat MS Natalizumab, an anti-alpha-4 integrin antibody, inhibits passage of leukocytes across the blood-brain barrier; given as a monthly infusion, it reduces number of exacerbations and new brain lesions but may increase the risk of progressive multifocal leukoencephalopathy (PML).